AstraZeneca Fined $72 Mil. In Europe For Blocking Omeprazole Generic
Executive Summary
AstraZeneca delayed market entry of omeprazole generics in Europe by supplying misleading patent information and deregistering the capsule formulation of its proton pump inhibitor Losec in certain countries, the European Commission said June 15